Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for June 2024InvestorPlace • 06/26/24
Corcept Announces Presentation of Results From Prevalence Phase of CATALYST Clinical Trial at American Diabetes Association's Scientific SessionsGlobeNewsWire • 06/24/24
Corcept Therapeutics (CORT) is a Top-Ranked Momentum Stock: Should You Buy?Zacks Investment Research • 06/14/24
Corcept Therapeutics Announces Presentations of Results of Pivotal Phase 3 GRACE Trial Evaluating Relacorilant in Patients with Hypercortisolism (Cushing's Syndrome)GlobeNewsWire • 06/03/24
Corcept (CORT) Up 24.5% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 05/31/24
Levi & Korsinsky, LLP Notifies Shareholders of Corcept Therapeutics Incorporated (CORT) an Upcoming Claims Deadline in a Class Action SettlementAccesswire • 05/07/24
Corcept (CORT) Upgraded to Strong Buy: Here's What You Should KnowZacks Investment Research • 04/17/24
Corcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing's SyndromeGlobeNewsWire • 04/01/24
Corcept Therapeutics Announces Fourth Quarter and Full-Year 2023 Audited Financial Results and Provides Corporate UpdateGlobeNewsWire • 02/15/24
Corcept Announces Preliminary Results From Prevalence Phase Of CATALYST Clinical TrialGlobeNewsWire • 02/15/24
Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results, Provide Corporate Update and Host Conference CallGlobeNewsWire • 02/08/24
Will Corcept (CORT) Beat Estimates Again in Its Next Earnings Report?Zacks Investment Research • 01/29/24
Corcept (CORT) Surges 5.1%: Is This an Indication of Further Gains?Zacks Investment Research • 01/04/24